Containing At Least Two Hetero Rings Bridged Or Fused Among Themselves Or Bridged Or Fused With A Common Carbocyclic Ring System, (e.g., Rifamycin, Etc.) Patents (Class 435/119)
-
Patent number: 5460814Abstract: The present invention relates to the compound A of the formula (A), the related compound B, carboxylic acid derived from acid anhydride group of these compounds and esters and salts thereof, microorganisms for producing the compounds, methods for producing the compounds A and/or B by using the microorganisms, and a treated or untreated fermentation broth obtained by culturing strains belonging to genus Zopfiella or Zopfiella curvata No. 37-3 strain. ##STR1## The present invention provides the compounds A and B, derivatives thereof, and treated or untreated fermentation broth obtained by culturing the strains belonging to genus Zopfiella or Zopfiella curvata No. 37-3 strain, which show an excellent activities as antifungal agent and anti-thrombotic agent.Type: GrantFiled: April 18, 1994Date of Patent: October 24, 1995Assignee: Nissan Chemical Industries, Ltd.Inventors: Tsuneo Watanabe, Takeshi Yasumoto, Michio Murata, Michito Tagawa, Hiroyuki Narushima, Takashi Furusato, Masao Kuwahara, Masami Hanaue, Tatsuya Seki
-
Patent number: 5459141Abstract: Compounds 31668P and 31668U, a process for their production and their use.Compound 31668P and compound 31668U with the formulae ##STR1## have an antibiotic and an antitumor action.Type: GrantFiled: June 17, 1993Date of Patent: October 17, 1995Assignee: Hoechst AktiengesellschaftInventors: Laslo Vertesy, Joachim Betz, Hans-Wolfram Fehlhaber, Matthias Helsberg, Herbert Kogler, Michael Limbert, Dieter-Andreas Sukatsch, Ramaiyer R. Chandran, Bimal N. Ganguli
-
Patent number: 5457039Abstract: The present invention relates to a method for producing high amounts of Monascus pigment by cultivating a Monascus species in a particularly prepared media to which rice powder and peptone are added as carbon and nitrogen sources, respectively.Type: GrantFiled: September 9, 1993Date of Patent: October 10, 1995Assignee: Lotte Confectionery Co., Ltd.Inventors: Jun-Sung Kim, Kee-Hyun Choi, Jang-Youn Choi, Yoon-Soo Lee, Ik-Boo Kwon
-
Patent number: 5451581Abstract: This invention relates to the antibiotics LL-14E605.beta. and O-methyl-LL-14E605.beta. derived from the microorganism Sebekia benihana which are useful as antibacterial agents.Type: GrantFiled: May 21, 1993Date of Patent: September 19, 1995Inventors: May D. Lee, Peter T. Northcote, Mary Lechevalier
-
Patent number: 5445952Abstract: The present invention relates to a method to enhance a cell's ability to produce biotin precursors and/or biotin by deregulating at least one enzyme of the fatty acid biosynthetic pathway in the cell, preferably an enzyme that carries out an early step in the pathway. Preferably, the biotin biosynthetic pathway is also deregulated. The invention includes biotin-producing cells in which at least one enzyme of the fatty acid biosynthetic pathway is deregulated, preferably by transforming the cells with nucleic acid sequences encoding at least one of those enzymes; methods to produce such cells; and use of such cells to produce biotin.Type: GrantFiled: January 22, 1993Date of Patent: August 29, 1995Assignee: BASF AktiengesellschaftInventors: John W. Campbell, Alex Cheung, Christina K. Eddy
-
Patent number: 5431896Abstract: Described is a new immunosuppressant, L-687,819, a C-31 demethylated derivative of L-683,795 (FK-523), produced under fermentation conditions utilizing the new mutant microorganism, Streptomyces hygroscopicus subsp. ascomyceticus (Merck Culture Collection MA 6646) ATCC No. 53855, being a blocked mutant of Streptomyces hygroscopicus subsp. ascomyceticus (MA 6475) ATCC No. 14891. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.Type: GrantFiled: July 30, 1992Date of Patent: July 11, 1995Assignee: Merck & Co., Inc.Inventors: Louis Kaplan, Robert P. Borris, Kevin M. Byrne, Linda S. Wicker, Deborah L. Zink
-
Patent number: 5432067Abstract: There is disclosed a process for the production of biotin, in which a culture of a microorganism of the genus Sphingomonas, having an ability to produce biotin, is prepared in a medium, and biotin produced and accumulated in the medium is collected. Also disclosed are microorganisms of the genus Sphingomonas, having an ability to produce biotin, which are useful for this production process of the present invention.Type: GrantFiled: August 25, 1993Date of Patent: July 11, 1995Assignee: Sumitomo Chemical Company, LimitedInventors: Kazuo Kumagai, Misao Miki, Emiko Kawano, Satoshi Mitsuda
-
Patent number: 5429940Abstract: The present invention provides a process for producing oxazopyrroloquinolines which comprises culturing microorganisms to produce pyrroloquinolinequinone and adding .alpha.-amino acids or monomethylamine to the resulting culture broth which contains the pyrroloquinolinequinone and from which cells of microorganisms are not separated, thereby to convert the pyrroloquinolinequinone to the corresponding oxazopyrroloquinolines. The thus obtained oxazopyrroloquinolines include novel compounds. The present invention further provides aldose reductase inhibitors, diabetic combined disease curing agents, immunopotentiating agents and liver disease inhibiting agents which contain as active ingredient these oxazopyrroloquinolines having excellent physiological activity.Type: GrantFiled: July 12, 1993Date of Patent: July 4, 1995Assignee: Mitsubishi Gas Chemical CompanyInventors: Teizi Urakami, Mitsunori Oda, Chieko Itoh, Hisao Kobayashi, Toshio Nagai, Kazuhiro Sugamura
-
Patent number: 5426108Abstract: This invention relates to antibiotic 31F508.alpha..sub.1 of the formula ##STR1## 31F508.alpha..sub.2, 31F508.beta..sub.1 and 31F508.beta..sub.2, derived from the microorganism Streptomyces viridodiastaticus subsp. "littus" which are useful as anti-bacterial agents.Type: GrantFiled: November 10, 1993Date of Patent: June 20, 1995Assignee: American Cyanamid CompanyInventor: Joseph A. Zaccardi
-
Patent number: 5418168Abstract: This invention relates to new agents designated LL-F28249.alpha., LL-F28249.beta., LL-F28249.gamma., LL-F28249.delta., LL-F28249.epsilon., LL-F28249.zeta., LL-F28249.eta., LL-F28249.theta., LL-F28249.iota., LL-F28249.kappa., LL-F28249.lambda., LL-F28249.mu., LL-F28249.nu., and LL-F28249.omega., to their production by fermentation, to methods for their recovery and concentration from crude solutions, to processes for their purification and to pharmaceutically and pharmacologically-acceptable salts thereof. The present invention includes within its scope the biologically pure culture which produces there agents, derived from a newly-discovered and previously uncultured microorganism, Streptomyces cyaneogriseus subsp. noncyanogenus, NRRL 15773.Type: GrantFiled: August 10, 1992Date of Patent: May 23, 1995Assignee: American Cyanamid CompanyInventors: Guy T. Carter, Margaret J. Torrey, Michael Greenstein
-
Patent number: 5407815Abstract: R-(-)-1-(5-Hydroxyhexyl)-3-methyl-7-propylxanthine, a process for its preparation, and pharmaceuticals which contain this compound and which are suitable, in particular, for the prophylaxis and treatment of cerebral vascular disorders.Type: GrantFiled: December 21, 1990Date of Patent: April 18, 1995Assignee: Hoechst AktiengesellschaftInventors: Harald Furrer, Ulrich Gebert, Karl Rudolphi
-
Patent number: 5403738Abstract: An acidic polycyclic ether antibiotic, having structure established by X-ray crystallography, is formed by fermentation of a novel microorganism, Actinomadura sp. ATCC 53764. This novel antibiotic is useful as an anticoccidial in chickens, in the prevention or treatment of swine dysentery, and as a growth promotant in cattle and swine.Type: GrantFiled: December 17, 1993Date of Patent: April 4, 1995Assignee: Pfizer Inc.Inventors: John P. Dirlam, Walter P. Cullen, Hiroshi Maeda, Junsuke Tone
-
Patent number: 5399711Abstract: Two thiomarinol derivatives, which have antibacterial and anti-mycoplasmal properties, are obtainable from microorganisms of the genus Alteromonas and are named "thiomarinol B" and "thiomarinol C". Thiomarinol B can also be prepared by the oxidation of thiomarinol.Type: GrantFiled: September 20, 1993Date of Patent: March 21, 1995Assignee: Sankyo Company, LimitedInventors: Shuji Takahashi, Hideyuki Shiozawa, Katsumi Fujimoto, Yuji Iwano, Koichi Hirai, Akio Torikata, Takeshi Kagasaki, Kaneo Ogawa, Yoshiharu Sakaida, Kentaro Kodama, Akira Ishii
-
Patent number: 5399675Abstract: This invention relates to novel acidic polycyclic ether antibiotics CP-91,243 and CP-91,244 of the formula ##STR1## wherein R is H in CP-91,243 and R is CH.sub.3 in CP-91,244. The invention also relates to novel Actinomadura roseorufa microorganisms; processes for producing the novel antibiotics and the known antibiotic UK-58,852; methods for controlling coccidial infections in poultry, enteritis in livestock and swine dysentery; methods for promoting growth and/or improving efficiency of feed utilization in ruminant or monogastric animals; and nutrient feed compositions.This is a National filing under 35 U.S.C. 371 based on PCT/US89/02400 filed Jun. 1, 1989.Type: GrantFiled: November 5, 1991Date of Patent: March 21, 1995Assignee: Pfizer Inc.Inventor: Edward J. Tynan, III
-
Patent number: 5387515Abstract: Two enzymes, one an acetylmorphine carboxyesterase (AMCE), the other a morphine dehydrogenase (MDH), have been isolated from bacteria. The AMCE degrades heroin to morphine and the MDH oxidizes morphine to morphinone, with the aid of a cofactor. More particularly, the invention pertains to a process for preparing a 6-ketone from morphine or a methyl or ethyl derivative thereof. The process comprises oxidizing morphine or an ether derivative in the presence of a morphine dehydrogenase and the cofactor NADP.sup.+. These reactions are used in detection of heroin (using the two reactions coupled together) or morphine. The enzymes can be incorporated in sensors for this purpose.Type: GrantFiled: January 19, 1994Date of Patent: February 7, 1995Assignee: British Technology Group LimitedInventors: Neil C. Bruce, Lauren D. G. Stephens, Christopher R. Lowe
-
Patent number: 5378617Abstract: A process for the production of a compound of formula (I) ##STR1## which comprises cultivating a microorganism of the genus Streptomyces capable of producing the compound of formula (I) in the presence of one or more fatty acids and/or salts, esters and amides of these acids, whereby the compound of formula (I) is produced, and if desired isolating the said compound. The fatty acid increases the yield of the formula (I) compound and is preferably isobutyric or valeric acid.Type: GrantFiled: August 24, 1992Date of Patent: January 3, 1995Assignee: American Cyanamid CompanyInventors: Martin Todd, Mark A. Haxell, Gordon C. Lawrence
-
Patent number: 5376678Abstract: By carrying out the fermentation of Streptomyces avermitilis ATCC 55278, a dried mycelium is obtained which, orally administered to animals, particularly to ovines, has an antiparasitic activity.Type: GrantFiled: April 30, 1993Date of Patent: December 27, 1994Assignees: Gnosis srl, Euroresearch srlInventors: M. Leonardo Cappelletti, Giacomo Lucarelli, Giuseppe Mearelli
-
Patent number: 5374554Abstract: A microorganism derived from a host microorganism capable of producing d-biotin by introducing a recombinant plasmid being incorporated with a biotin gene cloned from a microorganism of the genus Serratia capable of producing d-biotin and further integrating an exogenous biotin gene into the chromosome, and a process for preparing d-biotin which comprises cultivating the microorganism in a culture medium so that d-biotin is formed and accumulated in the culture medium and collecting the d-biotin. The microorganism of the invention has an extremely high productivity of d-biotin, and hence, d-biotin can be produced in a large amount by cultivating the microorganism of the invention.Type: GrantFiled: January 13, 1993Date of Patent: December 20, 1994Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Saburo Komatsubara, Yuji Imai, Makoto Masuda, Naoki Sakurai
-
Patent number: 5371000Abstract: A process for the production of ergoline derivatives of general formula I is described ##STR1## in which the bonds represent two single-bonds or a double bond and a single bond.R.sub.1 means a hydrogen atom or an alkyl group with 1-6 carbon atomsR.sub.2 symbolizes a hydrogen atom or an alkyl group with 1-6 carbon atoms,R.sub.3 represents a carboxyl group or a grouping of formula--CONR.sub.4 R.sub.5 or --NHCQNR.sub.6 R.sub.7with R.sub.4 and R.sub.5 meaning hydrogen or an alkyl radical with 1-6 carbons atoms optionally substituted by a hydroxy group and R.sub.6 and R.sub.7 meaning an alkyl group containing 1-4 carbon atoms and Q meaning an oxygen or sulfur atom.Type: GrantFiled: October 7, 1992Date of Patent: December 6, 1994Assignee: Schering AktiengesellschaftInventors: Heidi Hummel-Maquardt, Mario Kennecke, Alfred Weber, Klaus Nickisch, Gregor Haffer
-
Patent number: 5369021Abstract: A microorganism for selective production of a specific compound of avermectin having one or more of the following properties:specific accumulation of avermectin compound "a",effective incorporation of isoleucine or its keto acid (3-methyl-2-oxovaleric acid) into avermectin molecule, andmarkedly suppressed incorporation of valine or its keto acid (2-oxoisovaleric acid) into avermectin molecule.Type: GrantFiled: December 30, 1992Date of Patent: November 29, 1994Assignee: The Kitasato InstituteInventors: Omura Satoshi, Ikeda Haruo
-
Patent number: 5366880Abstract: A new antibiotic cyclic lipopeptide having the formula ##STR1## wherein R is H or OH and a method of producing is described. The agent has very high activity against human pathogens and is of very low mammalian toxicity.Type: GrantFiled: May 21, 1993Date of Patent: November 22, 1994Assignee: Merck & Co., Inc.Inventors: Robert E. Schwartz, Prakash S. Masurekar, David F. Sesin, Jerrold M. Liesch, Thomas C. Hallada, Otto D. Hensens
-
Patent number: 5352783Abstract: Microbial transformation of a macrolide immunosuppressant by the microorganism Streptomyces sp., (Merck Culture Collection MA 6960) ATCC No. 55387 yields a compound of the structural formula (I): ##STR1## This compound is an immunosuppressant useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases, the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.Type: GrantFiled: June 9, 1993Date of Patent: October 4, 1994Assignee: Merck & Co., Inc.Inventors: Ali Shafiee, Byron H. Arison, Shieh-Shung T. Chen, Randall R. Miller, Ralph A. Stearns
-
Patent number: 5346919Abstract: The present invention relates to the compound A of the formula (A), the related compound B, carboxylic acid derived from acid anhydride group of these compounds and esters and salts thereof, microorganisms for producing the compounds, methods for producing the compounds A and/or B by using the microorganisms, and a treated or untreated fermentation broth obtained by culturing strains belonging to genus Zopfiella or Zopfiella curvata No. 37-3 strain. ##STR1## The present invention provides the compounds A and B, derivatives thereof, and treated or untreated fermentation broth obtained by culturing the strains belonging to genus Zopfiella or Zopfiella curvata No. 37-3 strain, which show an excellent activities as antifungal agent and anti-thrombotic agent.Type: GrantFiled: August 2, 1993Date of Patent: September 13, 1994Assignee: Nissan Chemical Industries, Ltd.Inventors: Tsuneo Watanabe, Takeshi Yasumoto, Michio Murata, Michito Tagawa, Hiroyuki Narushima, Takashi Furusato, Masao Kuwahara, Masami Hanaue, Tatsuya Seki
-
Patent number: 5344768Abstract: Pyrrolo-quinoline quinone (PQQ) is microbiologically produced by culturing a bacterium in a medium containing methanol, methylamine or a mixture thereof as a carbon source and recovering PQQ from the culture medium. The bacteria are strains of Methylobacterium, Ancylobacter, Hyphomicrobium, Xanthobacter, Thiobacillus, Microcyclus and Achromobacter.Type: GrantFiled: July 14, 1993Date of Patent: September 6, 1994Assignee: Mitsubishi Gas Chemical Co., Inc.Inventor: Teizi Urakami
-
Patent number: 5336605Abstract: A process for the preparation of an adventive embryo of a plant belonging to the genus Podophyllum, comprising the steps of preparing cells of a plant belonging to the genus Podophyllum, incubating the cells in a sugar free medium or a medium containing up to 2% by weight sugar, and then incubating the cells in a medium containing more than 2% by weight of sugar to generate an adventive embryo; a process for the production of a podophyllotoxin compound comprising the steps of preparing an adventive embryo of a plant belonging to the genus Podophyllum, culturing the adventive embryo to generate an adventitious organ, culturing the adventitious organ to produce a podophyllotoxin compound, and recovering the podophyllotoxin compound; and a process for the production of a podophyllotoxin compound, comprising the steps of preparing de-differentiated cells or tissue of a plant belonging to the genus Podophyllum culturing the de-differentiated cells or tissue in a liquid medium to generate a differentiated organ, cuType: GrantFiled: February 1, 1993Date of Patent: August 9, 1994Assignee: Nippon Oil Company, Ltd.Inventors: Ko Sakata, Eitaroh Morita, Tetsuya Takezono
-
Patent number: 5332837Abstract: This invention concerns 2-acyl-4,5,8,8a-tetrahydro-4-oxycyclopropan[c]pyrrol(3,2-e) indole derivatives of Formula I': ##STR1## the compounds of Formula I' are useful as uv light absorber substances, as chemical intermediates and as prodrugs of known spirocyclopropylpyrroloindole CC-1065 analogs. Representative Formula I' compounds have been shown to possess useful ranges of antitumor activity in standard laboratory animal tests.Type: GrantFiled: January 22, 1993Date of Patent: July 26, 1994Assignee: The Upjohn CompanyInventors: Robert C. Kelly, David G. Martin, Paul A. Aristoff
-
Patent number: 5324742Abstract: The present invention relates to a novel aldose reductase inhibitor of the formula: ##STR1## wherein X is methylene or carbonyl;R is ##STR2## R.sup.1, R.sup.2, R.sup.3, and R.sup.4 each is hydrogen or lower alkyl, to a method for producing the inhibitor by culturing Crucibulum sp. RF-3817 or its variants, and to an agent for inhibiting an aldose reductase comprising the inhibitor.Type: GrantFiled: May 8, 1991Date of Patent: June 28, 1994Assignee: Shionogi & Co., Ltd.Inventors: Tadashi Yoshida, Toshiyuki Kato, Yoshimi Kawamura, Koichi Matsumoto, Hiroshi Itazaki
-
Patent number: 5324644Abstract: Described is a new process for producing the immunosuppressant, L-682,993, a C-31 demethylated derivative of L-679,934 (FK-506), produced under fermentation conditions utilizing the new mutant microorganism Streptomyces sp. (Merck Culture Collection MA 7017) ATCC No. 55334, being a blocked second generation mutant of Streptomyces sp. (MA 6858) ATCC No. 55098. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.Type: GrantFiled: July 28, 1992Date of Patent: June 28, 1994Assignee: Merck & Co., Inc.Inventors: Carolyn L. Ruby, Christine C. Chung, Byron H. Arison
-
Patent number: 5318895Abstract: Disclosed are new Aspergillus niger mutants which can be used for identifying active FK-506/ rapamycin type, or cyclosporin A type inununosuppressants in a broth, natural product extract, or composition exhibiting inununosuppressant activity. Specifically disclosed are the new mutants, ATCC No. 74085 (MF 5659), which is sensitive to FK-506 and rapamycin but resistant to cyclosporin A; ATCC No. 74086 (MF 5659) which is resistant to FK-506, cyclosporin A and rapamycin; and ATCC No. 74087 (MF 5661) which is resistant to FK-506 and rapamycin, but sensitive to cyclosporin A.Type: GrantFiled: October 5, 1992Date of Patent: June 7, 1994Assignee: Merck & Co., Inc.Inventors: Jennifer N. Kahn, Kevin M. Byrne, Louis Kaplan, Richard J. Monaghan
-
Patent number: 5318902Abstract: Several classes of water immiscible lipophilic phases effect the transfer of crystalline orange precursor pigments produced by Monascus species in an aqueous culture medium from the aqueous to the lipophilic phase without solubilizing a major portion of the pigment. Liquid vegetable and mineral oils are two such classes. This phenomenon permits high recovery of pigment in a simple and convenient manner, and also permits development of a batch recycle and a continuous fermentation process for pigment production.Type: GrantFiled: September 21, 1992Date of Patent: June 7, 1994Assignee: UOPInventor: Edward J. St. Martin
-
Patent number: 5310666Abstract: A Rhodotorula rubra strain has been found which reduces pentoxifylline to 100% to give the S-alcohol. Moreover, other oxoalkylxanthine derivatives can also be converted into the corresponding S-alcohol. The microbiologically obtained S-(+)-enantiomers can then be converted stereoselectively into the respective R-(-)-enantiomers. The corresponding S-alcohols and the R-alcohols obtained by enantioselective inversion of configuration cause an increase in cerebral blood flow.Type: GrantFiled: November 13, 1992Date of Patent: May 10, 1994Assignee: Hoechst AktiengesellschaftInventors: Werner Aretz, Harald Furrer, Ulrich Gebert, Heinz-Joachim Hinze
-
Patent number: 5310741Abstract: A compound of the formula ##STR1## wherein R.sup.1 is hydrogen or a hydrocarbon residue which may be substituted; R.sup.2 is oxo or hydrogen plus hydroxy which may be acylated; R.sup.3 is hydrogen or hydroxy which may be acylated; at least one of the dotted lines represents a single bond, or a salt thereof, produced from Penicillum thomii has potent RA-89 muscarinic receptor blocking activity and is of value as therapeutic agent for parkinsonism, ulcer, etc. or as mydriatics.Type: GrantFiled: April 22, 1991Date of Patent: May 10, 1994Assignee: Takeda Chemical Industries, Ltd.Inventors: Hideo Shirafuji, Shigetoshi Tsubotani, Takenori Ishimaru, Setsuo Harada
-
Patent number: 5292648Abstract: The compound of the formula ##STR1## and its tautomer are obtained from cultures of Eupenicillium sp. The compound has antifungal activity.Type: GrantFiled: February 18, 1993Date of Patent: March 8, 1994Assignee: Hoffmann-La Roche Inc.Inventors: Miyako Masubuchi, Toru Okuda, Hisao Shimada
-
Patent number: 5292647Abstract: A new microorganism, Streptomyces avermitilis subspecies niger NRRL 21005, and processes using the microorganism for producing known avermectins are provided.Type: GrantFiled: November 30, 1992Date of Patent: March 8, 1994Assignee: Eli Lilly and CompanyInventors: Rosanne Bonjouklian, Otis W. Godfrey, Tim A. Smitka, Raymond C. Yao
-
Patent number: 5290689Abstract: Described is a process for producing a new immunosuppressant, a C-19/C-22 cyclic hemiketal (Compound I) biotransformation analog of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces sp. (Merck Culture Collection MA6969) ATCC No. 55280. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.Type: GrantFiled: September 28, 1992Date of Patent: March 1, 1994Assignee: Merck & Co., Inc.Inventors: George M. Garrity, Magda M. Gagliardi, Shieh-Shung T. Chen
-
Patent number: 5290698Abstract: A novel antitumor substance BE-13793C or a pharmaceutically acceptable salt thereof, which is represented by the following formula: ##STR1## an anticancer agent comprising the novel substance or a pharmaceutically acceptable salt thereof, a method of producing the novel substance and a microorganism Streptoverticillium FERM P-10489, capable of producing the novel substance are disclosed.Type: GrantFiled: December 4, 1992Date of Patent: March 1, 1994Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Hiroyuki Suda, Katuhisa Kojiri, Akira Okura, Kenji Kawamura, Masanori Okanishi
-
Patent number: 5284758Abstract: This invention relates to a fungal microorganism Pseudodiplodia sp. (MF5767) isolated from bark discs of Hibiscus sp. and useful in a fermentation process to form compounds of formula (I): ##STR1## which are squalene synthetase inhibitors and thus useful as cholesterol lowering agents.Type: GrantFiled: August 14, 1992Date of Patent: February 8, 1994Assignee: Merck & Co., Inc.Inventors: Gerald F. Bills, Mary N. Omstead, Wendy H. Clapp, Fernando Pelaez
-
Patent number: 5284947Abstract: A compound having the structural formula ##STR1## or a pharmaceutically acceptable salts and prodrugs thereof, wherein R.sup.1 is selected from the group consisting of hydrogen and loweracyl, and R.sup.2 is selected from the group consisting of hydrogen, hydroxyl and methoxyl, as well as methods for the preparation and use thereof.Type: GrantFiled: September 15, 1992Date of Patent: February 8, 1994Assignee: Abbott LaboratoriesInventors: Sunil K. Kadam, Patrick E. Humphrey, Jill Hochlowski, James B. McAlpine, Marianna Jackson
-
Patent number: 5283183Abstract: Described is a process for producing a new immunosuppressant, a C-19/C-22 cyclic hemiketal (Compound I) biotransformation analog of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces sp. (Merck Culture Collection MA6971) ATCC No. 55282. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.Type: GrantFiled: September 28, 1992Date of Patent: February 1, 1994Assignee: Merck & Co., Inc.Inventors: George M. Garrity, Shieh-Shung T. Chen
-
Patent number: 5278053Abstract: Improved processes for producing a polyether antibiotic compound represented by A82810 comprising: (1) cultivating Actinomadura fibrosa sp. nov. NRRL 18348 or Actinomadura sp. NRRL 18880, (2) feeding acid hydrolyzed casein at a rate from about 2.50-7.50 gm/L/day, (3) feeding glucose at a rate from about 2.50-7.50 gm/L/day, and (4) feeding propionate at a rate from about 0.50-1.5 gm/L/day to the appropriate culture medium during fermentation, are provided.Type: GrantFiled: September 16, 1991Date of Patent: January 11, 1994Assignee: Eli Lilly and CompanyInventor: LaVerne D. Boeck
-
Patent number: 5270182Abstract: The novel compounds of formulas I and II ##STR1## have an antibiotic activity.Type: GrantFiled: May 7, 1992Date of Patent: December 14, 1993Assignee: Hoechst AktiengesellschaftInventors: Christopher M. M. Franco, Dilip J. Upadhyay, Louis E. L. Coutinho, Bimal N. Ganguli, Jurgen Blumbach, Hans-Wolfram Fehlhaber, Herbert Kogler
-
Patent number: 5270187Abstract: Described is a process for producing a new immunosuppressant, L-682,992, a C-13, C-31 demethylated ring-rearranged analog of L-679,934, under novel fermentation conditions utilizing the microorganism, Actinoplanacete Sp., (Merck Culture Collection MA 6559) ATCC No. 53771. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.Type: GrantFiled: January 21, 1992Date of Patent: December 14, 1993Assignee: Merck & Co., Inc.Inventors: Shieh-Shung T. Chen, Byron H. Arison, Linda S. Wicker
-
Patent number: 5268282Abstract: Described is a process for producing a new immunosuppressant, a C-19/C-22 cyclic hemiketal (Compound I) biotransformation analog of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces sp. (Merck Culture Collection MA6970) ATCC No. 55281. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.Type: GrantFiled: September 28, 1992Date of Patent: December 7, 1993Assignee: Merck & Co., Inc.Inventors: George M. Garrity, Shieh-Shung T. Chen
-
Patent number: 5268281Abstract: Described is a process for producing a new immunosuppressant, a C-19/C-22 cyclic hemiketal (Compound I) biotransformation analog of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces sp. (Merck Culture Collection MA6968) ATCC No. 55279. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.Type: GrantFiled: September 28, 1992Date of Patent: December 7, 1993Assignee: Merck & Co., Inc.Inventors: George M. Garrity, Magda M. Gagliardi, Shieh-Shung T. Chen
-
Patent number: 5266484Abstract: Disclosed is a method for selecting a mutant strain belonging to the genus Streptomyces which is a hyper-producer of Streptovaricin C superior to those know heretofore. This is accomplished by first subjecting a natural strain of Streptomyces spectabilis to conditions so as to isolate organisms which are streptovaricin resistant. The streptovaricin resistant organisms thus isolated are then subjected to mutagenesis and then cultured. The colonies which are asporogenous are individually cultured in fermentation batches such that the strains take the form of pellets of varying sizes and colors. From the batch having the most heterogeneous mixture of pellets, the smallest pellet or the pellet(s) having the deepest color (usually deep red or crimson) is isolated. We have discovered that the strain of this pellet has a high likelihood of being a hyperproducer of streptovaricin. The strain of this pellet may then be subjected to fermentation conditions to produce streptovaricin.Type: GrantFiled: April 23, 1992Date of Patent: November 30, 1993Assignees: Shin-Etsu Bio, Inc., Shin-Etsu Chemical Co., Ltd.Inventors: Kaname Inoue, Motohide Yamazaki, Kanji Murofushi, Richard W. Armentrout
-
Patent number: 5258291Abstract: A method for separation and recovery of polymeric beads from an antibiotic fermentation broth comprising suspending a mixture of the beads and any inherent mold from the fermentation in an aqueous solution having a specific gravity which is effective to cause the beads to form a discrete layer at or on the surface of the solution, separate and apart from the mold. The separate layer of the beads may then be easily removed from the liquid by a conventional physical methods.Type: GrantFiled: February 12, 1993Date of Patent: November 2, 1993Assignees: Shin-Etsu Bio. Inc., Shin-Etsu Chemical Co., Ltd.Inventors: Kaname Inoue, Motohide Yamazaki, Richard W. Armentrout
-
Patent number: 5258290Abstract: A process for the production of .beta.-carboline derivatives of general formula I ##STR1## in which X represents a hydrogen atom or a halogen atom,Y represents a carbon-oxygen bond or a methyl group,R.sub.1 represents an alkyl group with up to 6 carbon atoms andR.sub.2 represents an alkyl group with up to 4 carbon atoms,from 1,2,3,4-tetrahydro-.beta.-carboline derivatives of general formula II ##STR2## in which X, Y, R.sub.1 and R.sub.2 have the above-mentioned meaning, is described, which is characterized in that the 1,2,3,4-tetrahydro-.beta.-carboline derivatives are fermented with a fungi culture of genus Fusarium or Myrothecium.Type: GrantFiled: July 9, 1992Date of Patent: November 2, 1993Assignee: Schering AktiengesellschaftInventors: Alfred Weber, Mario Kennecke, Jean C. Hilscher, Klaus Nickisch
-
Patent number: 5252474Abstract: There are disclosed plasmids containing DNA isolated from Streptomyces avermitilis, the microorganism which is used to prepare avermectin compounds, identified as pAT1, pVE650 pVE855, pVE859, pVE1446, pVE923, and pVE924 which contain the genetic information for the biosynthesis of the avermectins. Methods for the isolation of such plasmid and for the manipulation of the plasmids to alter the formation of the avermectin compound are also disclosed.Type: GrantFiled: March 14, 1990Date of Patent: October 12, 1993Assignee: Merck & Co., Inc.Inventors: Keith M. Gewain, Douglas J. MacNeil, Tanya MacNeil, Philip S. Paress, Carolyn L. Ruby, Stanley L. Streicher
-
Patent number: 5252612Abstract: Described is a new immunosuppressant, L-683,756, a bisdemethylated, ring rearranged derivative of L-683,590, produced under fermentation conditions utilizing the microorganism, Actinoplanacete sp. (Merck Culture Collection MA 6559) ATCC No. 53771. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.Type: GrantFiled: June 24, 1992Date of Patent: October 12, 1993Assignee: Merck & Co., Inc.Inventors: Byron H. Arison, Edward S. Inamine, Shieh-Shung T. Chen, Linda S. Wicker
-
Patent number: RE34698Abstract: Polyether type antibiotics are produced by culturing a polyether type antibiotic-producing microorganism is a medium containing a fatty acid or its precursor and ammonia or an ammonium salt or urea.Type: GrantFiled: January 29, 1993Date of Patent: August 16, 1994Assignee: Kaken Chemical Company, LimitedInventors: Yukio Miyazaki, Akira Shibata, Tateo Yahagi, Masayuki Hara, Kaoru Hara, Singo Yoneda, Hiroko Kasahara, Yuko Nakamura